Proffered Presentations

*current as of 3/4/2023*

PR001, A042  An endogenous molecular brake preventing APOBEC-driven tumor mutational burden, heterogeneity and AR therapy resistance. Ping Mu, UT Southwestern Medical Center, Dallas, Texas.


PR003, A050  Convergent evolution in DNA repair-deficient mCRPC in response to targeted therapy. David A. Quigley, University of California, San Francisco, California.

PR004, B009  Exploring the role of ASCL1 in neuroendocrine prostate cancer. Kathia E. Rodarte, UT Southwestern Medical Center, Dallas, Texas.


PR006  PMR-116, a novel inhibitor of ribosome biogenesis with antitumor activity in preclinical models of prostate cancer. Luc Furic, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

PR007, A003  ERG-driven luminal prostate cancers emerge from Ck5+/Nkx3.1+ basal cells. Weiran Feng, Memorial Sloan Kettering Cancer Center, New York, New York.

PR008  Molecular determinants of prostate cancer lineage plasticity. David W. Goodrich, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

PR009  Basal cell lineage plasticity in prostate homeostasis, repair and tumor initiation. Dong Gao, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China (Mainland).

PR010, B055  First-in-class TRPV6 inhibitors for the treatment of prostate cancer. Kimberley Beaumont, Uniques, St. Lucia, Queensland, Australia.

PR011  The carcinoma of prostate sequencing of tumor and clinical endpoints (CAPSTONE) project: a clinico-genomic resource to enable patient-centric genomic research and improve the actionability of genetic testing in metastatic prostate cancer. Marcin P. Cieslik, University of Michigan, Ann Arbor, Michigan.


PR013, B043  Unlocking the proteome of metastatic prostate cancer circulating tumor cells. Justin M. Drake, University of Minnesota-Twin Cities, Minneapolis, Minnesota.

PR014  Genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Li Jia, Brigham and Women's Hospital, Boston, Massachusetts.
PR015 Inhibition of androgen receptor signaling in castrate resistant prostate cancer in association with inhibition of glycolysis by targeting hexokinase 2 activity with pyrrolopyrimidine-based small molecules. Takuma Uo, University of Washington, Seattle, Washington.